Search

Your search keyword '"Bonanno, Silvia"' showing total 219 results

Search Constraints

Start Over You searched for: Author "Bonanno, Silvia" Remove constraint Author: "Bonanno, Silvia"
219 results on '"Bonanno, Silvia"'

Search Results

1. Physical activity practiced at a young age is associated with a less severe subsequent clinical presentation in facioscapulohumeral muscular dystrophy

3. Digital health and Clinical Patient Management System (CPMS) platform utility for data sharing of neuromuscular patients: the Italian EURO-NMD experience

5. Respiratory function in a large cohort of treatment-naïve adult spinal muscular atrophy patients: a cross-sectional study

8. Six‐minute walk test as outcome measure of fatigability in adults with spinal muscular atrophy treated with nusinersen.

10. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

11. Efgartigimod in generalized myasthenia gravis: A real‐life experience at a national reference center

12. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

13. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group

15. NGS-Based Genetic Analysis in a Cohort of Italian Patients with Suspected Inherited Myopathies and/or HyperCKemia

16. A human pan-genomic analysis reconfigures the genetic and epigenetic make up of facioscapulohumeral muscular dystrophy

20. MiR-146a in ALS: Contribution to Early Peripheral Nerve Degeneration and Relevance as Disease Biomarker

22. Adults with spinal muscular atrophy: a large-scale natural history study shows gender effect on disease

25. Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment

29. Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy

32. 6MWT as measure of motor function and endurance in SMA type 3 patients treated with nusinersen

33. Dysregulation of myomiRs as common pathogenic feature associated with muscle atrophy in ALS, SMA and SBMA: Evidence from animal models and human patients

35. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

38. LncRNAs Associated with Neuronal Development and Oncogenesis Are Deregulated in SOD1-G93A Murine Model of Amyotrophic Lateral Sclerosis

39. Dysregulation of Muscle-Specific MicroRNAs as Common Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from Animal Models and Human Patients

41. Favorable outcome of COVID-19 infection in a patient with congenital myasthenic syndrome

42. CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis

44. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3

46. Circulating MyomiRs as Potential Biomarkers to Monitor Response to Nusinersen in Pediatric SMA Patients

48. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

49. FM19G11 preserves blood-brain barrier structural and functional integrity by reducing astrocyte toxicity in a human-derived in vitro model of amyotrophic lateral sclerosis

50. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis

Catalog

Books, media, physical & digital resources